| ABALOPARATIDE |
Eladynos® |
THERAMEX AUSTRALIA PTY LTD |
Osteoporosis |
Jul 2025 |
Recommended |
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2021 |
Recommended |
| ABEMACICLIB |
Verzenio™ |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2022 |
Not Recommended |
| ABEMACICLIB |
Verzenio™ |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2023 |
Recommended |
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative
(HER2-) breast cancer |
Nov 2023 |
Recommended |
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
Castration resistant carcinoma of the prostate |
Jul 2021 |
Not Recommended |
| ABIRATERONE ACETATE |
Zytiga® |
Janssen-Cilag Pty Ltd |
Metastatic prostate cancer |
Mar 2021 |
Recommended |
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa®MPRED |
Sun Pharma ANZ Pty Ltd |
Prostate cancer |
Mar 2022 |
Not Recommended |
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa® MPRED |
Sun Pharma ANZ Pty Ltd |
Prostate cancer |
Nov 2022 |
Recommended |
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa® Mpred |
SUN PHARMA ANZ PTY LTD |
Metastatic hormone sensitive prostate cancer |
Jul 2023 |
Recommended |
| ABIRATERONE AND PREDNISOLONE |
Andriga-10 |
ACTOR PHARMACEUTICALS PTY LTD |
Castration resistant carcinoma of the prostate |
Jul 2025 |
Recommended |
| ABROCITINIB |
Cibinqo® |
Pfizer Australia Pty Ltd |
Atopic dermatitis |
Nov 2021 |
Not Applicable |
| ABROCITINIB |
Cibinqo® |
PFIZER AUSTRALIA PTY LTD |
Severe atopic dermatitis |
Nov 2024 |
Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2020 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Mar 2020 |
Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Relapsed and/or refractory mantle cell lymphoma (R/R MCL) |
Jul 2021 |
Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2021 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma |
Nov 2022 |
Not Applicable |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma. |
Mar 2023 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma |
Dec 2022 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2023 |
Recommended |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Mantle cell lymphoma |
Jul 2025 |
Recommended |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2025 |
Recommended |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Mantle cell lymphoma (MCL) |
Jul 2026 |
Pending PBAC outcome |
| ACICLOVIR |
Xorox® |
Clinect Pty Ltd |
Herpes simplex keratitis |
Mar 2021 |
Not Recommended |
| ADALIMUMAB |
Hadlima® |
Merck Sharp & Dome (Australia) Pty Ltd |
Severe Crohn disease; complex refractory fistulising Crohn disease; moderate to severe
ulcerative colitis; severe active juvenile idiopathic arthritis; adult patients with
a history of jovenile idiopathic arthritis; severe psoriatic arthritis; ankylosing
spondylitis; severe chronic plaque psoriasis; severe active rheumatoid arthritis |
Nov 2020 |
Deferred |
| ADALIMUMAB |
Hadlima® |
Merck, Sharp & Dohme (Australia) Pty Ltd |
Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis;
Severe chronic plaque psoriasis; Juvenile idiopathic arthritis; Severe crohn’s disease;
Refractory fistulising crohn’s disease; moderate to severe hidradenitis suppurativa |
Jul 2020 |
Recommended |
| ADALIMUMAB |
Hyrimoz® |
Sandoz Pty Ltd |
Crohn disease; Ulcerative colitis; Juvenile idiopathic arthritis; Fistulising Crohn
disease; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Chronic
plaque psoriasis; Hidradenitis suppurativa |
Mar 2020 |
Recommended |
| ADALIMUMAB |
Idacio® |
Fresenius Kabi Australia Pty Limited |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory Fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Nov 2020 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Moderate to severe hidradenitis suppurativa |
Nov 2019 |
Recommended |
| ADALIMUMAB |
Hadlima® |
Merck Sharp & Dome (Australia) Pty Ltd |
Severe Crohn disease; complex refractory fistulising Crohn disease; moderate to severe
ulcerative colitis; severe active juvenile idiopathic arthritis; adult patients with
a history of jovenile idiopathic arthritis; severe psoriatic arthritis; ankylosing
spondylitis; severe chronic plaque psoriasis; severe active rheumatoid arthritis |
Dec 2020 |
Not Recommended |
| ADALIMUMAB |
Abrilada® |
Pfizer Australia Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa. |
Jul 2021 |
Recommended |
| ADALIMUMAB |
Hulio® |
Alphapharm Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa. |
Nov 2021 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis. |
Nov 2021 |
Recommended |
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Jul 2022 |
Recommended |
| ADALIMUMAB |
|
CIPLA AUSTRALIA PTY LTD |
Severe Crohn disease; moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Jul 2023 |
Recommended |
| ADALIMUMAB |
Hadlima® |
Organon Pharma Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Nov 2023 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Vision threatening non-infectious uveitis |
Mar 2024 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease |
Mar 2024 |
Deferred |
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Complex refractory fistulising Crohn disease Ulcerative colitis Crohn disease Chronic
plaque psoriasis Hidradenitis suppurativa |
Mar 2024 |
Recommended |
| ADALIMUMAB |
Hyrimoz® |
SANDOZ PTY LTD |
Severe Crohn disease (CD) Moderate to severe ulcerative colitis (UC) Severe active
juvenile idiopathic arthritis (JIA) Complex refractory fistulising Crohn disease (CD)
Severe active rheumatoid arthritis (RA) Severe psoriatic arthritis (PsA) Ankylosing
spondylitis (AS) Severe chronic plaque psoriasis (CPP) Moderate to severe hidradenitis
suppurativa (HS) |
Jul 2024 |
Recommended |
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease (IMID) |
Dec 2024 |
Recommended |
| ADALIMUMAB |
Yuflyma® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Moderate to severe ulcerative colitis Severe juvenile idiopathic arthritis Severe
chronic plaque psoriasis Severe Crohn disease Vision-threatening non-infectious uveitis |
Mar 2026 |
Recommended |
| ADALIMUMAB |
Amgevita® |
AMGEN AUSTRALIA PTY LIMITED |
Crohn disease Ulcerative colitis Active juvenile idiopathic arthritis Complex refractory
fistulising Crohn disease Active rheumatoid arthritis Psoriatic arthritis Ankylosing
spondylitis Chronic plaque psoriasis Hidradenitis suppurativa |
Mar 2026 |
Recommended |
| ADALIMUMAB; UPADACITINIB |
|
ABBVIE PTY LTD |
All adalimumab indications except juvenile idiopathic arthritis. Severe active rheumatoid arthritis. |
Nov 2022 |
Not Recommended |
| ADRENALINE |
Anapen® |
Allergy Concepts Pty Ltd |
Acute allergic reaction with anaphylaxis |
Nov 2020 |
Recommended |
| ADRENALINE (EPINEPHRINE) |
Jext® Jnr; Jext® |
HEALTH TECHNOLOGY ANALYSTS PTY LIMITED |
Acute allergic reaction with anaphylaxis |
Jul 2024 |
Recommended |
| ADRENALINE (EPINEPHRINE) |
Neffy® |
SEQIRUS (AUSTRALIA) PTY LTD |
Acute allergic reaction with anaphylaxis |
Mar 2026 |
Recommended |
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
Subfoveal choroidal neovascularisation |
Jul 2019 |
Recommended |
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration |
Mar 2024 |
Not Applicable |
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
Diabetic macular oedema |
Mar 2024 |
Not Applicable |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Diabetic macular oedema |
May 2024 |
Recommended |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration |
May 2024 |
Recommended |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
(AMD) |
Nov 2024 |
Recommended |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Diabetic macular oedema (DMO) |
Nov 2024 |
Recommended |
| AFLIBERCEPT |
Afqlir® Enzeevu™ |
SANDOZ PTY LTD |
Macular oedema secondary to retinal vein occlusion (RVO) Diabetic macular oedema (DMO)
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
(AMD) |
Jul 2025 |
Recommended |
| AFLIBERCEPT |
Eydenzelt® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) |
Nov 2025 |
Recommended |
| AFLIBERCEPT |
Eydenzelt® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion
with macular oedema; Diabetic macular oedema; Subfoveal choroidal neovascularisation
due to age-related macular degeneration |
Jul 2026 |
Pending PBAC outcome |
| ALECTINIB |
Alecensa® |
ROCHE PRODUCTS PTY LTD |
Non-small cell lung cancer (NSCLC) |
May 2025 |
Recommended |
| ALIROCUMAB |
Praluent® |
Sanofi-aventis Australia Pty Ltd |
Hypercholesterolaemia |
Mar 2020 |
Recommended |
| ALIROCUMAB |
Praluent® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Hypercholesterolaemia |
Nov 2022 |
Not Applicable |
| ALIROCUMAB |
Praluent® |
Sanofi-Aventis Australia Pty Ltd |
Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia. |
Mar 2023 |
Recommended |
| AMIFAMPRIDINE |
Ruzurgi® |
The Trustee For Orspec Pharma Unit Trust |
Lambert-Eaton myasthenic syndrome |
Nov 2021 |
Not Recommended |
| AMIFAMPRIDINE |
Ruzurgi® |
The Trustee For Orspec Pharma Unit Trust |
Lambert-Eaton myasthenic syndrome |
Mar 2022 |
Recommended |
| AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED
FATTY ACIDS |
Neocate® Syneo |
Nutricia Australia Pty Limited |
Cows' milk protein enteropathy Severe cows' milk protein enteropathy with failure
to thrive Combined intolerance to cows' milk protein, soy protein and protein hydrolysate
formulae Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein
and soy protein Cows' milk anaphylaxis Severe intestinal malabsorption including short
bowel syndrome Eosinophilic oesophagitis |
Mar 2024 |
Recommended |
| AMINO ACID FORMULA WITH CARBOHYDRATE, VITAMINS, MINERALS AND TRACE ELEMENTS WITHOUT
PHENYLALANINE, SUPPLEMENTED WITH DOCOSAHEXAENOIC ACID |
PKU Synergy® |
Nutricia Australia Pty Ltd |
Phenylketonuria (PKU) |
Jul 2020 |
Not Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE WITHOUT METHIONINE |
HCU Easy® |
Orpharma Pty Ltd |
Pyridoxine non-responsive homocystinuria |
Nov 2019 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE WITHOUT PHENYLALANINE |
PKU Easy® |
Orpharma Pty Ltd |
Phenylketonuria (PKU) |
Nov 2019 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE WITHOUT PHENYLALANINE AND TYROSINE |
TYR Easy® |
Orpharma Pty Ltd |
Tyrosinaemia |
Nov 2019 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
MSUD Easy® |
Orpharma Pty Ltd |
Maple syrup urine disease |
Nov 2019 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE, VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Easy Microtabs Plus |
ORPHARMA PTY LTD |
Phenylketonuria (PKU) |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE, VITAMINS, MINERALS, TRACE ELEMENTS AND
MEDIUM CHAIN TRIGLYCERIDES |
Essential Care Jr® |
Cortex Health Pty Ltd |
Multiple food allergies and various gastrointestinal disorders and allergic conditions |
Mar 2021 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE, VITAMINS, MINERALS, TRACE ELEMENTS AND
MEDIUM CHAIN TRIGLYCERIDES |
Essential Care Jr |
CORTEX HEALTH PTY LTD |
Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae
Severe intestinal malabsorption including short bowel syndrome Eosinophilic oesophagitis
Cows' milk protein enteropathy Severe cows' milk protein enteropathy with failure
to thrive Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein
and soy protein Cows' milk anaphylaxis |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW IN TRYPTOPHAN |
Ga Gel® Ga Express 15® |
Vitaflo Australia Pty Limited |
Pyridoxine Dependent Epilepsy |
Nov 2020 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW IN TRYPTOPHAN |
GA explore5™ |
VITAFLO AUSTRALIA PTY LIMITED |
Glutaric aciduria type 1 Pyridoxine dependent epilepsy |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW IN TRYPTOPHAN |
- GA1 Anamix Infant®
- GA1 Anamix Junior®
|
NUTRICIA AUSTRALIA PTY LTD |
Pyridoxine‑Dependent Epilepsy (PDE) |
Jul 2026 |
Pending PBAC outcome |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT METHIONINE |
HCU Lophlex® |
Nutricia Australia Pty Ltd |
Pyridoxine non-responsive homocystinuria |
Jul 2020 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT METHIONINE |
HCU express 15® |
Vitaflo Australia Pty Ltd |
Pyridoxine non-responsive homocystinuria |
Jul 2021 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT METHIONINE, THREONINE AND VALINE
AND LOW IN ISOLEUCINE |
MMA/PA explore5™ |
VITAFLO AUSTRALIA PTY LIMITED |
Methylmalonic acidaemia Propionic acidaemia |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Lophex® |
Nutricia Australia Pty Ltd |
Phenylketonuria (PKU) |
Mar 2020 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU express 15® |
Vitaflo Australia Pty Ltd |
Phenylketonuria |
Jul 2021 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU express 20® |
Vitaflo Australia Pty Ltd |
Phenylketonuria |
Jul 2021 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Squeezie® |
VITAFLO AUSTRALIA PTY LIMITED |
Phenylketonuria |
Nov 2022 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Lophlex Select LQ |
Nutricia Australia Pty Limited |
Phenylketonuria |
Mar 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE AND TYROSINE |
TYR Lophlex® |
Nutricia Australia Pty Ltd |
Tyrosinaemia (TYR) |
Jul 2020 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE AND TYROSINE |
TYR express 15® |
Vitaflo Australia Pty Ltd |
Tyrosinaemia |
Jul 2021 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
MSUD Lophlex® |
Nutricia Australia Pty Ltd |
Maple Syrup Urine Disease (MSUD) |
Jul 2020 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
MSUD express 15® |
Vitaflo Australia Pty Ltd |
Maple syrup urine disease |
Jul 2021 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
MSUD express 15® |
VITAFLO AUSTRALIA PTY LIMITED |
Short-chain Enoyl co-A Hydratase (ECHS1) deficiency and 3-Hydroxyisobutyryl co-A Hydrolase
(HIBCH) deficiency |
Jul 2026 |
Pending PBAC outcome |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
- MSUD Anamix Infant®
- MSUD Anamix Junior®
- MSUD Lophlex LQ 20®
- MSUD Maxamum®
|
NUTRICIA AUSTRALIA PTY LTD |
Short-chain enoyl-CoA hydratase (ECHS1) deficiency |
Jul 2026 |
Pending PBAC outcome |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE
AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
MSUD explore5™ |
Vitaflo Australia Pty Limited |
Maple syrup urine disease |
Mar 2023 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE, ISOLEUCINE
AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
MSUD explore5® |
VITAFLO AUSTRALIA PTY LIMITED |
Short-chain Enoyl co-A Hydratase (ECHS1) deficiency and 3-Hydroxyisobutyryl co-A Hydrolase
(HIBCH) deficiency |
Jul 2026 |
Pending PBAC outcome |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, LOW PHENYLALANINE AND SUPPLEMENTED
WITH DOCOSAHEXAENOIC ACID AND ARACHIDONIC ACID |
PKU Explore® |
Vitaflo Australia Pty Ltd |
Phenylketonuria (PKU) |
Jul 2019 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT METHIONINE AND SUPPLEMENTED
WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
HCU explore5™ |
Vitaflo Australia Pty Limited |
Pyridoxine non-responsive homocystinuria |
Mar 2023 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT PHENYLALANINE AND TYROSINE
AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
TYR explore5™ |
Vitaflo Australia Pty Limited |
Tyrosinaemia |
Mar 2023 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS WITH MINERALS, WITHOUT VALINE, LEUCINE AND ISOLEUCINE
WITH DOCOSOHEXAENOIC ACID AND ARACHIDONIC ACID |
MSUD explore® |
Vitaflo Australia Pty Ltd |
Maple syrup urine disease |
Nov 2019 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS
WITHOUT PHENYLALANINE |
PKU Start |
Vitaflo Australia Pty Limited |
Phenylketonuria |
Mar 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS
WITHOUT PHENYLALANINE; AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE
AND TYROSINE; AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW
IN TRYPTOPHAN; AMINO ACID FORMULA WITH VITAMINS AND MMMINERALS WITHOUT METHIONINE,
THREONINE AND VALINE AND LOW IN ISOLEUCIINE; AMINO ACID FORMULA WITH VITAMINS AND
MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE |
Anamix Infant® Formulas |
Nutricia Australia Pty Ltd |
Phenylketonuria (PKU); Tyrosinaemia (TYR); Glutaric Aciduria Type 1; Methylmalonic
acidaemia and Propionic acidaemia; Proven pyridoxine non-responsive homocystinuria;
Proven maple syrup urine disease |
Jul 2020 |
Recommended |
| AMINO ACID SYNTHETIC FORMULA SUPPLEMENTED WITH LONG CHAIN POLYUNSATURATED FATTY ACIDS |
EleCare® LCP |
Abbott Australasia Pty Ltd |
Cows' milk protein enteropathy; Severe cows' milk protein enteropathy with failure
to thrive; Combined intolerance to cows' milk protein, soy protein and protein hydrolysate
formulae; Cows' milk anaphylaxis; Proven combined immunoglobulin E (IgE) mediated
allergy to cows' milk protein and soy protein; Severe intestinal malabsorption including
short bowel syndrome. |
Mar 2023 |
Recommended |
| AMINO ACID SYNTHETIC FORMULA SUPPLEMENTED WITH LONG CHAIN POLYUNSATURATED FATTY ACIDS
AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED
FATTY ACIDS |
Neocate LCP® Neocate Syneo® |
Nutricia Australia Pty Ltd |
Cow’s milk allergy, multiple food intolerance and other medical conditions where an
amino acid-based formula is recommended |
Mar 2020 |
Recommended |
